Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

LifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)

Tipranks - Tipranks - Mon Mar 31, 2025

In a report released today, Charles Zhu from LifeSci Capital maintained a Hold rating on Repare Therapeutics (RPTX – Research Report). The company’s shares closed today at $0.99.

Don't Miss Our End of Quarter Offers:

Zhu covers the Healthcare sector, focusing on stocks such as Merus, Mersana Therapeutics, and Repare Therapeutics. According to TipRanks, Zhu has an average return of -13.8% and a 30.00% success rate on recommended stocks.

Repare Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.67.

See today’s best-performing stocks on TipRanks >>

RPTX market cap is currently $44.64M and has a P/E ratio of -0.52.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RPTX in relation to earlier this year. Earlier this month, Steve Forte, the EVP & CFO of RPTX sold 6,884.00 shares for a total of $7,847.76.

Read More on RPTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).